Author(s): Kavita M. Chaudhari, Tushar R. Chandan, Chandrashekhar D. Patil, Kajal V. Pansare, Jubershaha S. Fakir, Sunil K. Mahajan

Email(s): kavitachoudhari888@gmail.com

DOI: 10.52711/ijnmr.2026.44   

Address: Kavita M. Chaudhari1*, Tushar R. Chandan1, Chandrashekhar D. Patil2, Kajal V. Pansare2, Jubershaha S. Fakir2, Sunil K. Mahajan3
1K K Wagh Education Society’s, K K Wagh College of Pharmacy, Amrutdham, Nashik, Maharashtra, India – 422003.
2Department of Pharmacology, SSS’s Divine College Pharmacy, Nampur Road, Satana, Nashik, Maharashtra, India - 423301.
3Department of Chemistry, SSS’s Divine College Pharmacy, Nampur Road, Satana, Nashik, Maharashtra, India - 423301.
*Corresponding Author

Published In:   Volume - 5,      Issue - 4,     Year - 2026


ABSTRACT:
Huntington's disease (HD) is a neurodegenerative disorder characterized by severe motor, cognitive, and psychiatric symptoms. Patients of all ages can present with a dysfunction of the nervous system, which leads to the progressive loss of movement control and disabilities in speech, swallowing, communication, etc. The molecular basis of the disease is well understood, as HD is associated with a mutated gene, specifically a trinucleotide expansion, which encodes the huntingtin protein. This protein is linked to neurogenesis, and the loss of its function leads to neurodegenerative disorders. Although the genetic cause of the disorder has been known for decades, no effective treatment is yet available to prevent the onset or to eliminate the progression of symptoms. Thus, the present review focuses on the development of novel methods for the timely and accurate diagnosis of HD, to aid the development of therapies that may reduce the severity of symptoms and control their progression. The majority of the therapies include gene-silencing mechanisms of the mutated huntingtin gene, aiming to suppress its expression, and the use of various substances as drugs with highly promising results. In the present review, the latest approaches to the diagnosis of HD are discussed along with the need for genetic counseling and an up-to-date presentation of the applied treatments.


Cite this article:
Kavita M. Chaudhari, Tushar R. Chandan, Chandrashekhar D. Patil, Kajal V. Pansare, Jubershaha S. Fakir, Sunil K. Mahajan. Emerging Approaches in the Scientific Study of Huntington's Disease: A Review. A and V Pub International Journal of Nursing and Medical Research.2026; 5(4):212-0. doi: 10.52711/ijnmr.2026.44

Cite(Electronic):
Kavita M. Chaudhari, Tushar R. Chandan, Chandrashekhar D. Patil, Kajal V. Pansare, Jubershaha S. Fakir, Sunil K. Mahajan. Emerging Approaches in the Scientific Study of Huntington's Disease: A Review. A and V Pub International Journal of Nursing and Medical Research.2026; 5(4):212-0. doi: 10.52711/ijnmr.2026.44   Available on: https://ijnmronline.com/AbstractView.aspx?PID=2026-5-4-10


9. REFERENCES:
1.    Recabarren D, Alarcon M. Gene networks in neurodegenerative disorders. Life Sci. 2017; 183: 83–97.
2.    Pihlstrøm L, Wiethoff S, Houlden H. Genetics of neurodegenerative diseases: An overview. Handb Clin Neurol. 2017; 145: 309–323.
3.    Shen T, You Y, Joseph C, Mirzaei M, Klistorner A, Graham SL, et al. BDNF polymorphism: A review of its diagnostic and clinical relevance in neurodegenerative disorders. Aging Dis. 2018; 9: 523.
4.    Guzman-Martinez L, Maccioni RB, Andrade V, Navarrete LP, Pastor MG, Ramos-Escobar N. Neuroinflammation as a common feature of neurodegenerative disorders. Front Pharmacol. 2019; 10: 1008.
5.    Ma MW, Wang J, Zhang Q, Wang R, Dhandapani KM, Vadlamudi RK, et al. NADPH oxidase in brain injury and neurodegenerative disorders. Mol Neurodegener. 2017; 12: 7.
6.    Mendez MF. Early-onset Alzheimer's disease and its variants. Continuum (Minneap Minn). 2019; 25: 34–51.
7.    Bakels HS, Roos RAC, van Roon-Mom WMC, de Bot ST. Juvenile-onset Huntington disease pathophysiology and neurodevelopment: A review. Mov Disord. 2022; 37: 16–24.
8.    Kumar A, Kumar V, Singh K, Kumar S, Kim YS, Lee YM, et al. Therapeutic advances for Huntington's disease. Brain Sci. 2020; 10: 43.
9.    Yanagisawa N. The spectrum of motor disorders in Huntington's disease. Clin Neurol Neurosurg. 1992; 94(Suppl): S182–S184.
10.    Bonner-Jackson A, Long JD, Westervelt H, Tremont G, Aylward E, Paulsen JS. Cognitive reserve and brain reserve in prodromal Huntington's disease. J Int Neuropsychol Soc. 2013; 19: 739–750.
11.    Harrington DL, Liu D, Smith MM, Mills JA, Long JD, Aylward EH, et al. Neuroanatomical correlates of cognitive functioning in prodromal Huntington disease. Brain Behav. 2014; 4: 29–40.
12.    Epping EA, Mills JA, Beglinger LJ, Fiedorowicz JG, Craufurd D, Smith MM, et al. Characterization of depression in prodromal Huntington disease in the PREDICT-HD study. J Psychiatr Res. 2013; 47: 1423–1431.
13.    van Dijk JG, van der Velde EA, Roos RA, Bruyn GW. Juvenile Huntington disease. Hum Genet. 1986; 73: 235–239.
14.    Siesling S, Vegter-van der Vlis M, Roos RA. Juvenile Huntington disease in the Netherlands. Pediatr Neurol. 1997; 17: 37–43.
15.    Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A. 2004; 101: 3498–3503.
16.    Quarrell OWJ, Brewer HM, Squitieri F, Barker R, Nance MA, Landwehrmeyer GB. Juvenile Huntington’s Disease (and other trinucleotide repeat disorders). Oxford: Oxford University Press; 2009.
17.    Gatto EM, Parisi V, Etcheverry JL, Sanguinetti A, Cordi L, Binelli A, et al. Juvenile Huntington disease in Argentina. Arq Neuropsiquiatr. 2016; 74: 50–54.
18.    Tereshchenko A, Magnotta V, Epping E, Mathews K, Espe-Pfeifer P, Martin E, et al. Brain structure in juvenile-onset Huntington disease. Neurology. 2019; 92: e1939–e1947.
19.    Van der Plas E, Langbehn DR, Conrad AL, Koscik TR, Tereshchenko A, Epping EA, et al. Abnormal brain development in child and adolescent carriers of mutant huntingtin. Neurology. 2019; 93: e1021–e1030.
20.    Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi RE, et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature. 1983; 306: 234–238.
21.    Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993; 72: 971–983.
22.    Saudou F, Humbert S. The biology of huntingtin. Neuron. 2016; 89: 910–926.
23.    Schultz JL, van der Plas E, Langbehn DR, Conrad AL, Nopoulos PC. Age-related cognitive changes as a function of CAG repeat in child and adolescent carriers of mutant huntingtin. Ann Neurol. 2021; 89: 1036–1040.
24.    Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, et al. Relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet. 1993; 4: 398–403.
25.    Squitieri F, Jankovic J. Huntington's disease: How intermediate are intermediate repeat lengths? Mov Disord. 2012; 27: 1714–1717.
26.    LW, Brown R, Maxwell M, Wyttenbach A, Rubinsztein DC. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in mammalian cell models of Huntington's disease. J Med Genet. 2001; 38: 450–452.
27.    Shirasaki DI, Greiner ER, Al-Ramahi I, Gray M, Boontheung P, Geschwind DH, et al. Network organization of the huntingtin proteomic interactome in mammalian brain. Neuron. 2012; 75: 41–57.
28.    Nuzzo MT, Marino M. Estrogen/Huntingtin: A novel pathway involved in neuroprotection. Neural Regen Res. 2016; 11: 402–403.
29.    Leavitt BR, van Raamsdonk JM, Shehadeh J, Fernandes H, Murphy Z, Graham RK, et al. Wild-type huntingtin protects neurons from excitotoxicity. J Neurochem. 2006; 96: 1121–1129.
30.    Ismailoglu I, Chen Q, Popowski M, Yang L, Gross SS, Brivanlou AH. Huntingtin protein is essential for mitochondrial metabolism, bioenergetics and structure in murine embryonic stem cells. Dev Biol. 2014; 391: 230–240.
31.    Guedes-Dias P, Pinho BR, Soares TR, de Proença J, Duchen MR, Oliveira JM. Mitochondrial dynamics and quality control in Huntington's disease. Neurobiol Dis. 2016; 90: 51–57.
32.    Brustovetsky N. Mutant huntingtin and elusive defects in oxidative metabolism and mitochondrial calcium handling. Mol Neurobiol. 2016; 53: 2944–2953.
33.    Grima JC, Daigle JG, Arbez N, Cunningham KC, Zhang K, Ochaba J, et al. Mutant huntingtin disrupts the nuclear pore complex. Neuron. 2017; 94: 93–107.e6.
34.    Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet. 1995; 11: 155–163.
35.    McKinstry SU, Karadeniz YB, Worthington AK, Hayrapetyan VY, Ozlu MI, Serafin-Molina K, et al. Huntingtin is required for normal excitatory synapse development in cortical and striatal circuits. J Neurosci. 2014; 34: 9455–9472.
36.    Mehler MF, Petronglo JR, Arteaga-Bracho EE, Gulinello ME, Winchester ML, Pichamoorthy N, et al. Loss of huntingtin in medial and lateral ganglionic lineages disrupts neuronal subtypes and promotes Huntington disease-associated hallmarks. J Neurosci. 2019; 39: 1892–1909.
37.    Jung R, Lee Y, Barker D, Correia K, Shin B, Loupe J, et al. Mutations causing Lopes-Maciel-Rodan syndrome are huntingtin hypomorphs. Hum Mol Genet. 2021; 30: 135–148.
38.    Lackie RE, Maciejewski A, Ostapchenko VG, Marques-Lopes J, Choy WY, Duennwald ML, et al. The Hsp70/Hsp90 chaperone machinery in neurodegenerative diseases. Front Neurosci. 2017; 11: 254.
39.    Qi L, Zhang XD, Wu JC, Lin F, Wang J, DiFiglia M, et al. Role of chaperone-mediated autophagy in huntingtin degradation. PLoS One. 2012; 7: e46834.
40.    Keum JW, Shin A, Gillis T, Mysore JS, Abu Elneel K, Lucente D, et al. HTT CAG-expansion mutation determines age at death but not disease duration in Huntington disease. Am J Hum Genet. 2016; 98: 287–298.
41.    Dulski J, Sulek A, Krygier M, Radziwonik W, Slawek J. False-negative tests in Huntington's disease: A new variant within primer hybridization site. Eur J Neurol. 2021; 28: 2103–2105.
42.    De Luca A, Morella A, Consoli F, Fanelli S, Thibert JR, Statt S, et al. A novel triplet-primed PCR assay to detect the full range of trinucleotide CAG repeats in the huntingtin gene (HTT). Int J Mol Sci. 2021; 22: 1689.
43.    Langfelder P, Gao F, Wang N, Howland D, Kwak S, Vogt TF, et al. MicroRNA signatures of endogenous huntingtin CAG repeat expansion in mice. PLoS One. 2018; 13: e0190550.
44.    Reed ER, Latourelle JC, Bockholt JH, Bregu J, Smock J, Paulsen JS, et al. MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study. Neurology. 2018; 90: e264–e272.
45.    Glidden AM, Luebbe EA, Elson MJ, Goldenthal SB, Snyder CW, Zizzi CE, et al. Patient-reported impact of symptoms in Huntington disease: PRISM-HD. Neurology. 2020; 94: e2045–e2053.
46.    Paulsen JS, Miller AC, Hayes T, Shaw E. Cognitive and behavioral changes in Huntington disease before diagnosis. Handb Clin Neurol. 2017; 144: 69–91.
47.    Oosterloo M, de Greef BTA, Bijlsma EK, Durr A, Tabrizi SJ, Estevez-Fraga C, et al. Disease onset in Huntington's disease: When is the conversion? Mov Disord Clin Pract. 2021; 8: 352–360.
48.    Squadrone S, Brizio P, Abete MC, Brusco A. Trace elements profile in the blood of Huntington's disease patients. J Trace Elem Med Biol. 2020; 57: 18–20.
49.    Caron NS, Wright GEB, Hayden MR. Huntington disease. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington; 1993–2021. Updated 2020 Jun 11.
50.    Shoulson I, Young AB. Milestones in Huntington disease. Mov Disord. 2011; 26: 1127–1133.
51.    Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. Incidence and prevalence of Huntington's disease: A systematic review and meta-analysis. Mov Disord. 2012; 27: 1083–1091.
52.    Sobel SK, Cowan DB. Impact of genetic testing for Huntington disease on the family system. Am J Med Genet. 2000; 90: 49–59.
53.    Migliore S, Jankovic J, Squitieri F. Genetic counseling in Huntington's disease: Potential new challenges on the horizon. Front Neurol. 2019; 10: 453.
54.    MacLeod R, Metcalfe A, Ferrer-Duch M. A family systems approach to genetic counseling: Development of narrative interventions. J Genet Couns. 2021; 30: 22–29.
55.    Pierron L, Hennessy J, Tezenas du Montcel S, Coarelli G, Heinzmann A, Schaerer E, et al. Informing about genetic risk in families with Huntington disease: Comparison of attitudes across two decades. Eur J Hum Genet. 2021; 29: 672–679.
56.    Barker RA, Fujimaki M, Rogers P, Rubinsztein DC. Huntingtin-lowering strategies for Huntington's disease. Expert Opin Investig Drugs. 2020; 29: 1125–1132.
57.    Aziz NA, van der Burg JMM, Tabrizi SJ, Landwehrmeyer GB. Overlap between age at onset and disease progression determinants in Huntington disease. Neurology. 2018; 90: e2099–e2106.
58.    Tabrizi SJ, Ghosh R, Leavitt BR. Huntingtin-lowering strategies for disease modification in Huntington's disease. Neuron. 2019; 101: 801–819.
59.    Lane RM, Smith A, Baumann T, Gleichmann M, Norris D, Bennett CF, et al. Translating antisense technology into a treatment for Huntington's disease. Methods Mol Biol. 2018; 1780: 497–523.
60.    Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, et al. Targeting huntingtin expression in patients with Huntington's disease. N Engl J Med. 2019; 380: 2307–2316.
61.    Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A. 2005; 102: 5820–5825.
62.    DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, Sass M, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A. 2007; 104: 17204–17209.
63.    Keiser MS, Kordasiewicz HB, McBride JL. Gene suppression strategies for dominantly inherited neurodegenerative diseases: Lessons from Huntington's disease and spinocerebellar ataxia. Hum Mol Genet. 2016; 25(R1): R53–R64.
64.    Yu D, Pendergraff H, Liu J, Kordasiewicz HB, Cleveland DW, Swayze EE, et al. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell. 2012; 150: 895–908.
65.    Dufour BD, Smith CA, Clark RL, Walker TR, McBride JL. Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice. Mol Ther. 2014; 22: 797–810.

Recomonded Articles:

A and V Pub International Journal of Nursing and Medical Research (IJNMR) is an international, peer-reviewed journal devoted to nursing and medical sciences. IJNMR's aim is to promote excellence in nursing and health care through the publication of clinical information and original research....... Read more >>>

RNI:                      
DOI:  


Journal Policies & Information



Popular Articles


Recent Articles




Tags